Journal of the Egyptian National Cancer Institute · 2026
Pilot study on RECAF (Receptor for Alpha-Fetoprotein) expression in pediatric acute leukemia: insights from flow cytometry analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Youssef Soha Raouf, Mohammady Mohamed Hany, Zaiema Shams ElDoha Galal ElDin
Аннотация
BACKGROUND: Acute leukemia is the most common cancer in children, highlighting the importance of early diagnosis. RECAF is an AFP receptor that is abnormally re-expressed in various malignant tumors, serving as a promising biomarker for tumors.
AIM: This study aimed to assess the clinical utility of RECAF expression by flow cytometry immunophenotyping in pediatric de novo acute leukemia patients.
METHODS: Our study was conducted in 80 pediatric patients with acute leukemia, comprising 40 newly diagnosed ALL patients, 40 newly diagnosed AML patients, and 40 age- and sex-matched non-malignant control subjects. Flow cytometric analysis for the Acute Leukemia panel and RECAF expression was performed on all subjects, along with other laboratory and clinical parameters.
RESULTS: Our study revealed that RECAF expression was significantly higher in patients with acute leukemia than in controls. We also established a cutoff of ≥ 13.31% for positive RECAF expression by flow cytometry to distinguish RECAF-positive acute leukemia patients from FECAF-negative patients and normal controls.
CONCLUSION: Our findings suggest that RECAF could be an important biomarker for differentiating leukemic blasts and may become a useful tool for monitoring measurable residual disease in the future. Such advancements have the potential to improve clinical outcomes and enhance patient monitoring and management for this high-risk group.
AIM: This study aimed to assess the clinical utility of RECAF expression by flow cytometry immunophenotyping in pediatric de novo acute leukemia patients.
METHODS: Our study was conducted in 80 pediatric patients with acute leukemia, comprising 40 newly diagnosed ALL patients, 40 newly diagnosed AML patients, and 40 age- and sex-matched non-malignant control subjects. Flow cytometric analysis for the Acute Leukemia panel and RECAF expression was performed on all subjects, along with other laboratory and clinical parameters.
RESULTS: Our study revealed that RECAF expression was significantly higher in patients with acute leukemia than in controls. We also established a cutoff of ≥ 13.31% for positive RECAF expression by flow cytometry to distinguish RECAF-positive acute leukemia patients from FECAF-negative patients and normal controls.
CONCLUSION: Our findings suggest that RECAF could be an important biomarker for differentiating leukemic blasts and may become a useful tool for monitoring measurable residual disease in the future. Such advancements have the potential to improve clinical outcomes and enhance patient monitoring and management for this high-risk group.